Last updated: May 25, 2026
Ledipasvir and sofosbuvir are sourced through a multi-tier supply chain spanning API manufacture, key intermediates (nucleoside and NS5A inhibitor fragments), contract synthesis, and finished-dose production. The supplier base concentrates in China and India for API and intermediates, with finished-dose manufacturing often split between China, India, and the EU/US for specific commercial markets.
Which companies supply ledipasvir (API) and ledipasvir-based combination drugs?
Ledipasvir is commonly supplied as API or in-drug combination components used in ledipasvir/sofosbuvir fixed-dose products (marketed globally as Harvoni in many territories). The practical supplier set for ledipasvir is dominated by API and intermediate producers capable of scale, regulatory compliance, and stable supply of advanced heterocycles and stereochemically controlled intermediates.
Primary ledipasvir API supplier types
- API manufacturers producing ledipasvir drug substance under GMP for finished-dose licensees.
- Key intermediate and chiral intermediate suppliers producing late-stage building blocks used for ledipasvir synthesis.
- Finished-dose contract manufacturers producing ledipasvir/sofosbuvir tablets for brand and generic markets using sourced APIs.
How to identify the ledipasvir API supplier in practice
- Check the FDA “Drug Substance” and “Drug Product” facility listings in drug master files, CDER supplements, and CMC sections for each product NDA/ANDA.
- Cross-reference DMF/Drug Master File holders and approved manufacturing sites associated with specific NDCs (where publicly disclosed).
- Track inspection outcomes in FDA and EU databases for sites producing NS5A inhibitors.
Which companies supply sofosbuvir (API) and sofosbuvir-based combination drugs?
Sofosbuvir has a broader and more mature supplier ecosystem than many other direct-acting antivirals because it is a well-established nucleoside analogue with standardized routes to intermediates and high-volume commercial demand.
Primary sofosbuvir API supplier types
- Nucleoside API producers with process control for phosphorylation-resistant intermediates and final conversion to the active triphosphate prodrug precursor.
- Nucleobase and sugar intermediate suppliers producing the coupled intermediates used in the sofosbuvir synthesis route.
- Finished-dose tablet manufacturers producing sofosbuvir combinations.
Sofosbuvir supply chain pattern
- Commonly layered sourcing for the right-to-supply pathway:
- Sugar and nucleobase intermediate sourcing,
- Key coupling intermediate synthesis,
- Final sofosbuvir API finishing and crystallization,
- Tablet formulation and packaging under GMP.
What are the main ledipasvir/sofosbuvir finished-dose suppliers (tablets) by market?
Finished-dose ledipasvir/sofosbuvir tablets require:
- Tablet formulation development,
- Stability-controlled granulation and compression,
- Blister and bottle packaging lines,
- GMP release under the drug product applicant’s quality system.
Typical finished-dose manufacturing geographies
- India: large number of generic and contract manufacturing plants supporting global exports.
- China: broad base for API and intermediates, plus tablet manufacturing for export and some branded supply.
- EU and US: fewer plants, usually tied to specific brand supply and regulatory history.
Where finished-dose suppliers can differ
Even when the API supplier is the same, the tablet supplier can change between:
- Labeler (MAH holder),
- NDA vs. ANDA licensee,
- Market-specific packaging and distribution requirements.
How many API and intermediate suppliers exist for ledipasvir and sofosbuvir?
The supplier count depends on:
- Regulatory submissions (DMFs and ANDAs),
- Number of approved manufacturing sites per API,
- Geographic market coverage.
In practice, both molecules have a multi-supplier landscape, with:
- fewer high-capacity, high-compliance API nodes for ledipasvir,
- more widely distributed capacity for sofosbuvir.
This matters for continuity of supply and negotiation leverage: the API supply for sofosbuvir tends to have more options, while ledipasvir tends to have tighter constraints.
Which contract manufacturing organizations (CMOs) provide ledipasvir/sofosbuvir tablets?
For commercial supply, CMOs are used when:
- Brand holders outsource final formulation and packaging,
- Generic manufacturers outsource tablet processing for scale and regulatory speed.
Cottage-level manufacturers generally cannot meet:
- API traceability requirements,
- controlled environmental and process documentation,
- stability protocol expectations tied to combination therapeutics.
A robust CMO for ledipasvir/sofosbuvir usually demonstrates:
- multi-site GMP coverage,
- validated blending, compression, dissolution, and uniformity controls,
- documented bioequivalence and dissolution justification for generics.
What APIs and intermediates constrain supply for ledipasvir/sofosbuvir?
Supply risk concentrates in late-stage and stereochemically controlled steps rather than early building blocks.
Ledipasvir bottlenecks (typical)
- Stereocenter formation steps and late-stage coupling,
- impurity control for complex heterocycle intermediates,
- crystallization control for consistent polymorphic profile.
Sofosbuvir bottlenecks (typical)
- nucleoside intermediate coupling steps,
- phosphorylation-prodrug stability controls during isolation and drying,
- consistent particle size and moisture control.
What are the Orange Book and regulatory implications for supplier selection?
For supplier procurement and risk management, the regulatory implication is practical:
- suppliers need to support approved commercial product supply and consistent CMC documentation,
- any change in manufacturing site can trigger supplement needs, stability rework, and re-qualification.
Even without litigation involvement, regulatory friction can reduce supplier flexibility for combination products.
How do supplier changes affect ledipasvir/sofosbuvir generic entry and launch timelines?
For ANDA products, the supplier set impacts:
- API sourcing lead times for qualification batches,
- CMC comparability documentation timelines,
- inspection outcomes at the API and drug product sites.
Generic entrants with constrained API sources often delay stability submission and manufacturing readiness, pushing launch windows.
What is the competitive landscape for sourcing ledipasvir and sofosbuvir?
Competition tends to cluster around:
- companies with both API and tablet capabilities,
- vertically integrated intermediate and API producers,
- contract manufacturers with established nucleotide and NS5A inhibitor know-how.
Procurement leverage is typically higher for sofosbuvir due to a broader supplier base, while ledipasvir can be more constrained based on synthesis complexity and impurity control capability.
Key Takeaways
- Ledipasvir and sofosbuvir supply is multi-tier: API, key intermediates, and tablet manufacturing.
- Sofosbuvir usually has a broader, more flexible API supplier landscape than ledipasvir.
- Supplier qualification is driven by GMP history, impurity control capability, and CMC readiness for the specific finished-dose product.
- Supplier substitution can affect regulatory timelines because CMC changes require re-qualification and stability strategy alignment.
FAQs
- What documentation do buyers need to qualify an ledipasvir/sofosbuvir API supplier?
- How do API polymorph and crystallization differences impact sofosbuvir batch release?
- Which manufacturing sites typically become bottlenecks for ledipasvir tablet production under GMP?
- What CMC changes trigger regulatory supplements when switching ledipasvir API suppliers?
- How should procurement teams price risk when ledipasvir supply is constrained vs sofosbuvir?
References
No sources were provided in the prompt, and no web-accessible dataset or filings were supplied. Therefore, no citations can be generated.
